Asset
NATALIZUMAB
Revenue
No revenue reported in loaded filings.
Clinical trials (31)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01416181 | phase3 | terminated | 2011-09-13 | 2015-07-28 | Biogen | A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis |
| NCT00078611 | phase3 | completed | 2004-03-01 | 2005-03-01 | Biogen | A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease |
| NCT00744679 | phase4 | completed | 2008-11-01 | 2008-12-01 | Biogen | A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State |
| NCT00831649 | phase2 | terminated | 2004-09-01 | 2005-02-01 | Biogen | A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201 |
| NCT00771043 | phase4 | withdrawn | 2008-11-01 | 2009-08-01 | Biogen | A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| BLA 125104 | BLA | Biogen Inc. |
Marketed products (1)
- TYSABRI